Pfeiffer syndrome FGFR1 Variant Analysis

Test Background

Pfeiffer syndrome is divided into three subtypes with types 2 and 3 being more common and severe than type 1, which has a better overall prognosis. Type 1 is characterized by craniosynostosis, midface hypoplasia, broad and medially deviated thumbs and great toes, and varying degrees of brachydactyly. Other findings may include hearing loss and/or hydrocephalus. Intellect is typically normal. Types 2 and 3 have more extreme craniosynostosis, significant proptosis, and broad and medially deviated thumbs and great toes. Other findings may include choanal stenosis/atresia, laryngotracheal abnormalities, hydrocephalus, and seizures. In addition type 2 may have cleft palate. Developmental delay/intellectual disability is common in both. Pfeiffer syndrome is inherited in an autosomal dominant manner. Variants may be inherited from an affected parent or may be de novo. Approximately 5% of Pfeiffer syndrome type 1 cases are due to the p.Pro252Arg mutation in the FGFR1 gene, while the remaining 95% of cases are due to sequence variants in the FGFR2 gene. This laboratory performs targeted variant analysis for p.Pro252Arg in the FGFR1 gene as well as Sanger sequencing of the FGFR2 gene.

Gene(s): 

FGFR1

About Claritas

Claritas Genomics serves children affected with complex genetic disorders by providing timely and accurate results, resolving families’ long search for answers. By combining clinical expertise of the world’s best pediatric specialists with innovative platform solutions, Claritas is working to improve patient care and enable new discoveries. We are committed to the highest quality and accessibility of information and our interpretive services and unique approach to reporting set the standard for reliably and clearly communicating genetic information.

Now is the time to integrate genomics into clinical practice to inform, guide and improve medical treatment for kids around the world.